| Bioactivity | LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2). | ||||||||||||
| Target | IC50: 0.68 μM (HT29); 0.6 μM (OVCAR-3); 16 μM (AsPC-1); 0.14 μM (PC-3) | ||||||||||||
| Invitro | LP-184 inhibits the growth of HT29, OVCAR-3, AsPC-1 and PC-3, with GI50s of 0.68, 0.6, 16 and 0.14 μM, respectively[1].LP-184 displays IC50s of 800nM and 210 nM for anti-cancer activitie in the thymidine incorporation into cellular DNA (2 hour) and Trypan blue (48 hour) assay[1]. | ||||||||||||
| In Vivo | LP-184 (7.5 and 10 mg/kg; i.p.; 21 day) has potent 15 anti-tumor activity against MV522 tumors, producing 4/6 and 5/5 partial responses, respectively[1]. Animal Model: | ||||||||||||
| Name | LP-184 | ||||||||||||
| CAS | 924835-67-6 | ||||||||||||
| Formula | C16H20N2O4 | ||||||||||||
| Molar Mass | 304.34 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Trevor C. Mcmorris, et al. Illudin analogs useful as anticancer agents. WO2007019308A2. |